BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the target cut. The analyst views Humacyte’s early commercial traction as evidence of the “game-changing nature” of its Acellular Tissue Engineered Vessel.
Light Up your Portfolio with Spark:
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HUMA:
Disclaimer & DisclosureReport an Issue
